Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes
Enrique Caballé‐Perez(Instituto Nacional de Cancerología), Óscar Arrieta(Instituto Nacional de Cancerología)
Cited by 5
Related Papers
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
|JAMA Oncology|2020|153
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
|Journal of Clinical Oncology|2022|133